Christensen R et al. - Rosehip powder does reduce pain; accordingly it may be of interest as a nutraceutical, although its efficacy and safety need evaluation and independent replication in a future large-scale/long-term trial. Methods
A study to evaluate the efficacy of rosehip powder for symptomatic treatment of OA
OA pts were randomized to either rosehip or placebo
The primary outcome was reduction in pain
As secondary analysis the number of responders to therapy was analyzed as Odds Ratios (OR)
Restricted Maximum Likelihood (REML) methods were applied for the meta-analyses using mixed effects models
Results
The 3 studies showed a reduction in pain scores by rosehip powder (145 pts) vs placebo (142 pts)
Test for homogeneity seemed to support that the efficacy was consistent across trials
It seemed twice as likely that a patient allocated to rosehip powder would respond to therapy vs placebo
See all
